Diabetes Type II Presentation Grading Rubric Oral Presentati

Diabetes Type Ii Presentationgrading Rubric Oral Presentation100 Poin

Diabetes Type II Presentationgrading Rubric Oral Presentation100 Poin

Diabetes Type II Presentation GRADING RUBRIC: ORAL PRESENTATION 100 points total 10% of grade

CRITERIA MAX. POINTS EARNED POINTS

Abstract (Introduction) provided is less than 150 words (A brief overview of the background of the topic are provided). 10%

An exemplar or case study using the system is presented and discussed. 10%

Pathophysiology of the System 15%

Clinical Manifestations 10%

Diagnostic Studies/ Laboratories 10%

Clinical Management/ Treatment Modalities 15%

Evaluation of Treatments 10%

Patient Education and Safety (QSEN) 10%

Class discussion is facilitated 10%

TOTAL 100%

Paper For Above instruction

Type II diabetes mellitus (T2DM) has emerged as a major public health concern worldwide, driven by rising obesity rates, sedentary lifestyles, and genetic predispositions. This presentation aims to explore the multifaceted aspects of T2DM, encompassing its pathophysiology, clinical manifestations, diagnostics, management strategies, and patient education initiatives essential for effective control. An exemplar case study involving a middle-aged patient with newly diagnosed T2DM will be discussed to contextualize these concepts and demonstrate practical application.

The abstract for this presentation provides a succinct overview of the background, significance, and scope of T2DM, ensuring it remains under 150 words. Understanding the pathophysiology is crucial; T2DM primarily involves insulin resistance and eventual pancreatic beta-cell dysfunction, leading to hyperglycemia. This metabolic disturbance results from genetic factors coupled with lifestyle influences that impair glucose uptake and utilization. The clinical manifestations are variable but often include polyuria, polydipsia, polyphagia, unexplained weight loss, and fatigue. Recognizing these signs early facilitates prompt diagnosis and management.

Diagnostic studies for T2DM rely on laboratory tests such as fasting plasma glucose, oral glucose tolerance test (OGTT), and hemoglobin A1c levels. These tools help confirm the diagnosis and gauge disease severity. Management strategies focus on lifestyle modifications—including diet and exercise—and pharmacotherapy, such as metformin and insulin, tailored to individual needs. Regular monitoring of blood glucose levels and HbA1c ensures therapeutic efficacy. Evaluation of treatments involves assessing glycemic control, comorbid conditions, and potential side effects, adjusting therapy as needed.

Patient education plays a pivotal role in T2DM management, emphasizing medication adherence, dietary adjustments, physical activity, and foot care, aligned with QSEN (Quality and Safety Education for Nurses) standards. Safety measures, including monitoring for hypoglycemia and recognizing signs of hyperglycemia, are integral to patient empowerment and preventing complications.

The case study involves a 50-year-old with obesity, sedentary habits, and a family history of diabetes who presents with classic symptoms. Diagnostic results confirm hyperglycemia. The management plan involves lifestyle counseling, initiation of metformin, and regular follow-up. Patient education focuses on understanding the condition, medication use, and lifestyle changes to improve outcomes. This case illustrates how an integrated approach can effectively manage T2DM and mitigate long-term complications.

In conclusion, T2DM represents a complex, multifactorial disease demanding a comprehensive management approach. Educating patients, early diagnosis, and personalized treatment are key to controlling the disease and reducing its burden on individuals and healthcare systems.

References

  • American Diabetes Association. (2023). Standards of Medical Care in Diabetes—2023. Diabetes Care, 46(Supplement 1), S1–S144.
  • Colberg, S. R., et al. (2016). Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care, 39(11), 2065-2079.
  • DeFronzo, R. A. (2018). Pathogenesis of type 2 diabetes mellitus. Medical Clinics of North America, 102(1), 5-13.
  • Desouza, C., et al. (2004). Hypoglycemia: Clinical presentation and management. American Journal of Medicine, 117(8), 592-598.
  • Inzucchi, S. E., et al. (2015). Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Diabetes Care, 38(1), 140-149.
  • Reaven, G. M. (2011). Insulin resistance: The link between obesity and cardiovascular disease. The Medical Clinics of North America, 95(2), 341-347.
  • Sands, C. (2018). Diabetes mellitus: Pathophysiology and management. Journal of Clinical Medicine, 7(11), 391.
  • Van Gaal, L. F., et al. (2006). Management of obesity. The Medical Clinics of North America, 90(6), 1119-1132.
  • World Health Organization. (2020). Diabetes Fact Sheet. WHO. https://www.who.int/news-room/fact-sheets/detail/diabetes
  • Zimmet, P., et al. (2016). The global epidemiology of type 2 diabetes mellitus and the associated burden of complications. Diabetes and Metabolism, 42(5), 340-347.

Related Assignments